foxo4-dri senolytic human trial PDF) Peptide Selectively Removes Senescent Cells From in vitro Expanded Chondrocytes FOXO4-DRI: Human Trial Status, Cancer

[4] Other symptoms may include shortness of breath, feeling faint, a smooth red tongue, pale skin, chest pain, nausea and vomiting, loss of appetite, heartburn, numbness in the hands and feet, difficulty walking, memory loss, muscle weakness, poor reflexes, blurred vision, clumsiness, depression, and confusion

no LD50 established even at very high doses in rodents No Hormonal Effects: Does not affect testosterone, estrogen, growth hormone, or other hormonal axes Gastric Origin: Derived from a naturally occurring human gastric protein, suggesting good biological compatibility Stability: Unusually stable in gastric acid, supporting oral administration potential Reported Effects: Anecdotal reports of fatigue, nausea in some research subjects TB-500 Safety Profile: (PMID: 20536472) Note: Published safety data is primarily available for Thymosin Beta-4

(1) BPC-157 is also commonly known as pentadecapeptide due to the 15 amino acids it is comprised of

Its your safety net for catching the contamination you can't see

The potential for NLY01 to protect the myelin sheath in the context of MS is unknown